NCT06906341Phase 2Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-08Estimated

Enrollment · participants270Estimated

Source updated2026-07-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-22 · 1 field changed

Enrollment · participant count

Recorded edit

− Previous value

count: 90; type: ESTIMATED

+ Updated value

count: 270; type: ESTIMATED

Check registry source

Study details

Conditions studied

Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms; Endometrial Cancer

Treatments or interventions studied

Relacorilant 150 mg once daily (QD)DrugAlso known as CORT125134
Nab-paclitaxel 80 mg/m^2Drug
Bevacizumab 10 mg/kgDrug

Primary outcomes · main study measures

measure: Progression-Free Survival (PFS); description: To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.; timeFrame: Date of first dose until PD or death, up to 18 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history